MHP Webpage Header Image v2r1

Creating accessible care options for patients—from their own homes.

PRA’s Mobile Health Platform (MHP) engages with patients wherever they are. Our app-based platform allows us to do everything that’s possible in a physician’s office or clinical site, virtually.

The same way you bank, sign documents, email, and text on your phone—we can do all of that within a mobile environment for your trial.

Download our Mobile Health Platform fact sheet to learn more

Enhancing collaboration between all study stakeholders.

Our multi-language, multi country platform is designed with patients at the center—but we know that clinical breakthroughs would not be possible without seamless interaction between all stakeholders. Our fit-for-purpose solution provides access to data in real-time, speeding up the decision-making process and helping us get safe and effective treatments to patients faster than ever before.

Download our fact sheet to learn more

Mobile solutions to meet your unique needs.

Today, we have the ability to educate patients, gather electronic informed consent and e-signatures, and complete patient reported outcomes—right from the patient’s phone. Using connected devices, we can collect home healthcare data in the same mobile app and serve all of that data into the source for the clinical trial.



Enroll Patients with PI I/E Checklists, eSignatures, and Eligibility Adjudication
with Seamless IxRS and EDC Integration


Motivate, Engage, and Manage Patients and Stakeholders with App Reminders, Text/Email Messages and Payments


Collect Clinical Outcome Assessments PROs/ClinROs, eDiaries, IP Compliance, Symptoms, and mHealth Biometrics


Videotelephony for Remote Consent, Virtual Patient Visits, Central Raters, and Care Circle Engagement

Our digital health solutions are built with each specific trial in mind. Depending on the disease state, the patient population, and our sponsor’s targets, our experts will help determine what is most applicable to your particular trial. From enrollment and ongoing engagement efforts to consultations and in-depth analysis, we have the tools needed to conduct your hybrid or virtual trial from start to finish.

Read about PRA’s Decentralized Clinical Trial capabilities

Reducing the burden of participation for patients.

The traditional approach to clinical development requires 100% of visits to take place on-site, which places a huge burden on patients. We have the resources to change that.

If we can enable patients to complete 50% to 75% of clinical tasks in their mobile environment before arriving on-site, that site visit might only last an hour instead of five. It may seem small, but those four hours can have a meaningful impact for patients and site staff.

Chart screen randomize
Chart treatment prior
Chart radical prostatectomy
Chart post treatment
Chart end of treatment
Chart after rp

Screen and Randomize
<35 days before randomization

Treatment Prior to RP
Every 28 days, or as indicated (±2 days)

Radical Prostatectomy (RP)
Within 14 days

Post-treatment Follow-up Phase
“X” Months After EoT Visit

End of Treatment Visit
<30 days of last dose

Treatment After RP
Every 28 days, or as indicated (±2 days)

We identify ways to minimize time on-site, often replacing site visits with home healthcare visits and even full virtual visits—while still collecting necessary endpoints in a valid way. By incorporating mobile solutions, we can reduce the burden on patients and provide significant value to our sponsors.

Learn how wearable technologies are eliminating many traditional barriers of clinical trial participation.

Explore related content and topics